CPHI · XBRL financial data

China Pharma Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CPHI's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	1,098	1,803	2,150*	925	1,100	1,134*	1,136	1,026	756	1,226*	984	948
Cost of revenue	1,245	2,037	2,229*	1,940	1,620	1,295*	1,272	1,113	816	1,075*	698	865
Gross profit	(147)	(233)	(79)*	(1,015)	(520)	(161)*	(136)	(87)	(60)	151*	285	84
Research and development	24	46	148*	164	88	1*	30	21	40	190*	84	19
General and administrative	112	246	690*	92	345	859*	507	441	425	1,079*	1,226	1,377
Total operating expenses	310	480	1,105*	376	566	1,035*	623	565	568	1,351*	1,403	1,515
Operating income (loss)	(456)	(714)	(1,184)*	(1,392)	(1,085)	(1,196)*	(759)	(652)	(628)	(1,200)*	(1,117)	(1,432)
Interest income	1	2	3*	2	1	—	1	0	—	—	0	0
Interest expense	138	66	50*	7	7	7*	7	7	7	7*	9	9
Net income (loss)	(593)	(778)	(1,232)*	(1,438)	(1,118)	(1,224)*	(786)	(528)	(651)	(1,222)*	(1,143)	(1,458)
Earnings per share, basic USD per share	(0.06)	(0.06)	—	(0.09)	(0.06)	—	(0.24)	(0.16)	(0.17)	—	(0.04)	(0.04)
Earnings per share, diluted USD per share	(0.06)	(0.06)	—	(0.09)	(0.06)	—	(0.24)	(0.16)	(0.17)	—	(0.04)	(0.04)
Weighted average shares, basic thousands of shares	9,916	13,216	—	16,124	17,307	—	3,262	3,262	3,874	—	25,602	40,522
Weighted average shares, diluted thousands of shares	—	—	—	—	—	—	3,262	3,226	—	—	25,602	40,522

† Share count changed about 1/10 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 8x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (CPHI's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	902	1,370	1,424	739	700	600	400	600	268	345	168	305
Accounts receivable	—	368	504	255	333	232	329	269	225	241	196	182
Inventory	3,914	3,767	3,733	2,819	2,499	2,266	1,979	1,679	1,650	1,621	1,499	1,362
Total current assets	5,527	5,807	5,997	3,973	3,739	3,270	2,851	2,701	2,329	2,346	2,004	2,007
Property and equipment, net	8,341	7,768	7,100	5,817	5,306	4,883	4,777	4,626	4,502	4,392	4,304	4,220
Right-of-use asset	152	134	117	77	59	38	19	—	198	182	162	146
Total assets	15,704	15,352	16,469	14,261	13,466	14,888	14,217	13,767	15,805	30,999	45,144	44,710
Accrued liabilities	121	120	299	209	83	247	195	191	170	351	311	500
Total current liabilities	10,547	7,058	6,821	4,712	4,760	5,017	5,122	5,251	6,623	7,400	7,268	7,682
Lease liability, non-current	78	59	40	—	—	—	—	—	128	112	92	75
Total liabilities	11,352	9,241	9,015	6,853	6,937	7,140	7,247	7,305	7,491	8,260	8,120	8,529
Accumulated deficit	(37,281)	(38,058)	(39,290)	(41,684)	(42,802)	(44,027)	(44,812)	(45,341)	(45,992)	(47,214)	(48,357)	(49,816)
Total stockholders' equity	4,353	6,111	7,455	7,409	6,528	7,748	6,970	6,462	8,314	22,740	37,024	36,181
Total liabilities and equity	15,704	15,352	16,469	14,261	13,466	14,888	14,217	13,767	15,805	30,999	45,144	44,710
Common shares outstanding (cover page) thousands of shares	11,433	32,952	14,817	17,163	19,253	32,619	3,262	3,262	5,022	40,522	40,522	43,022

† Share count changed about 1/10 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 8x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (CPHI's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(593)	(778)	(1,232)*	(1,438)	(1,118)	(1,224)*	(786)	(528)	(651)	(1,222)*	(1,143)	(1,458)
Stock-based compensation	—	—	—	—	—	—	—	0	—	—	0	0
Depreciation and amortization	695*	683*	696*	739*	697*	448*	329	321*	356*	497*	—	—
Net cash from operating activities	(216)*	1,007*	(22)*	(73)*	(47)*	238*	(58)	291*	(237)*	152*	(55)	(33)*
Purchases of property and equipment	—	—	year only	—	(9)*	20*	58	(0)*	1*	0*	—	—
Net cash from investing activities	5*	(67)*	(5)*	—	9*	(273)*	(81)	(10)*	(41)*	(6)*	—	—
Net cash from financing activities	1*	(476)*	30*	7*	7*	7*	(70)	(29)*	(122)*	(73)*	(79)	120*
Net change in cash	(265)*	468*	54*	(100)*	(21)*	(92)*	(214)	212*	(357)*	77*	(177)	136*

† Share count changed about 1/10 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 8x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Healthy Extracts	190	2,067	306*	14.7M	—	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Theriva Biologics	11,337	0*	(3,085)*	45.9M	3.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.